# SORAYA (NCT04296890)

> A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04296890
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ImmunoGen, Inc.
- Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
- Interventions: Mirvetuximab Soravtansine
- Enrollment: 106
- Primary outcome: Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

## Commentary we found

- YouTube: 27
- Podcasts: 24
- X threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=soraya-nct04296890

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04296890", "email": "<work email>"}; the inbox owner confirms by the emailed link.